-
公开(公告)号：EP3645521A1
公开(公告)日：2020-05-06
申请号：EP18735304.0
申请日：2018-06-29
发明人： RIVA, Carlo , GRAZIANI, Davide , LONGHI, Matteo , CALLEGARI, Elisa , FRIGERIO, Fabio , ANGELICO, Patrizia
IPC分类号： C07D401/14 , C07D401/06 , C07D401/10 , C07D401/12 , C07D403/06 , C07D405/06 , C07D407/10 , C07D413/12 , C07D487/04 , C07D207/20 , C07D498/04 , C07D211/70 , C07D295/195 , A61P13/02 , A61K31/4545
-
公开(公告)号：EP3429565B1
公开(公告)日：2021-06-09
申请号：EP17712937.6
申请日：2017-03-14
-
公开(公告)号：EP2874611A1
公开(公告)日：2015-05-27
申请号：EP13739677.6
申请日：2013-07-18
IPC分类号： A61K9/20 , A61K31/192 , A61K31/196 , A61K31/4439
CPC分类号： A61K9/205 , A61K31/192 , A61K31/196 , A61K31/4439
摘要： A solid gastro-resistant delayed release pharmaceutical form obtained without using gastro-resistant film coating is described.
-
公开(公告)号：EP4389746A3
公开(公告)日：2024-07-03
申请号：EP22215635.8
申请日：2022-12-21
发明人： GRAZIANI, Davide , RIVA, Carlo , PIRONA, Lorenza , MENEGON, Sergio , TAZZARI, Valerio , FRIGERIO, Fabio
IPC分类号： C07D471/04 , C07D487/04 , A61P25/02 , A61K31/5025
CPC分类号： C07D471/04 , C07D487/04 , A61P25/02
摘要： This invention relates to compounds of formula I;
and their use as antagonists of P2X3 and P2X2/3 receptor activity, pharmaceutical compositions comprising such compounds, and methods of treatment therewith. Compounds of the invention can be used for the treatment and/or prevention of pain and chronic pain and tolerance to analgesic, respiratory disorders and dysfunctions, and treatment of overactive bladder, bladder pain syndrome, dysuria and in general in genitourinary diseases, cardiovascular disorders and more in general for the potential treatment of visceral organ diseases and disorders characterized by the involvement of P2X3 and P2X2/3 receptors.-
公开(公告)号：EP3525761A1
公开(公告)日：2019-08-21
申请号：EP17784260.6
申请日：2017-10-10
IPC分类号： A61K9/16 , A61K31/145 , A61K31/7024
-
公开(公告)号：EP3308773A1
公开(公告)日：2018-04-18
申请号：EP16193180.3
申请日：2016-10-11
IPC分类号： A61K9/16 , A61K31/145 , A61K31/7024
CPC分类号： A61K9/1617 , A61K9/0095 , A61K9/167 , A61K9/5084 , A61K31/145 , A61K31/7024 , A61K2300/00
摘要： Oral cysteamine formulation consisting of dry layered lipid matrix microparticles useful for treating cystinosis and neurodegenerative disorders are described.
摘要翻译： 描述了用于治疗胱氨酸血症和神经变性疾病的由干燥的分层脂质基质微粒组成的口服半胱胺制剂。
-
公开(公告)号：EP2874611B1
公开(公告)日：2016-09-14
申请号：EP13739677.6
申请日：2013-07-18
IPC分类号： A61K9/20 , A61K31/192 , A61K31/196 , A61K31/4439
CPC分类号： A61K9/205 , A61K31/192 , A61K31/196 , A61K31/4439
-
公开(公告)号：EP2268617B1
公开(公告)日：2011-11-23
申请号：EP09714576.7
申请日：2009-02-25
IPC分类号： C07D217/20
CPC分类号： C07D217/20
摘要： A process for the resolution of racemic tetrahydropapaverine with optically active arylpropionic acids is described.
-
公开(公告)号：EP2268617A1
公开(公告)日：2011-01-05
申请号：EP09714576.7
申请日：2009-02-25
IPC分类号： C07D217/20
CPC分类号： C07D217/20
摘要： A process for the resolution of racemic tetrahydropapaverine with optically active arylpropionic acids is described.
摘要翻译： 描述了用旋光性芳基丙酸拆分外消旋四氢罂粟碱的方法。
-
公开(公告)号：EP3544584A1
公开(公告)日：2019-10-02
申请号：EP17800854.6
申请日：2017-11-20
发明人： BERLATI, Fabio , MENEGON, Sergio , FARINA, Pierluigi , PROVVEDINI, Diego , BARCHIELLI, Marco , MATTEI, Alberto
摘要： The present invention relates to a pharmaceutical formulation suitable for parenteral administration containing carglumic acid and a buffering agent having a pK a from 5.5 to 9.0 at 25°C; according to an embodiment, the buffering agent may have a pK a from 7.5 to 8.5, preferably a pK a of about 8.07, such as trometamol. The formulation may also contain at least one bulking agent, such as mannitol. The invention also includes a method for manufacturing a lyophilised sterile formulation by freeze-drying a water solution containing carglumic acid, a buffering agent having a pK a from 5.5 to 9.0 at 25°C, preferably from 7.5 to 8.5, and optionally a bulking agent to obtain a freeze-dried powder.
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.015 秒)
